

RECEIVED

9P1676

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

MAY 21 2001

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.

MAY 24 2001  
CON 001/CONF. #6620

#3  
DB  
5/25/01

TECH CENTER 1600/2900

In Re Application Of

Conrad et al.

Serial No.

09/780,752

Filing Date

February 9, 2001

Examiner

Unassigned

Group Art Unit

1646

Title:

Use of Relaxin Treat Diseases Related to Vasoconstriction.

Address to:

Assistant Commissioner for Patents  
Washington, D.C. 20231

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:

1. a Final Action under 37 CFR 1.113, or
  2. a Notice of Allowance under 37 CFR 1.311,
- whichever occurs first.

Also submitted herewith is:

- ☐ a certification as specified in 37 CFR 1.97(e);

OR

- ☐ the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).

## TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(c))

RECEIVED

Docket No.

COMM 01 Conf #6620

In Re Application Of:

Conrad et al.

TECH CENTER 1600/2900

Serial No.

09/780,752

Filing Date

February 9, 2001

Examiner

Unassigned

Group Art Unit

1646

Title:

Use of Relaxin Treat Diseases Related to Vasoconstriction.

## Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 50-0815 as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

## Certificate of Transmission by Facsimile\*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. \_\_\_\_\_)

on \_\_\_\_\_  
(Date)

Signature

Typed or Printed Name of Person Signing Certificate

## Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on 5/17/01 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Barbara M. Weatherly

Typed or Printed Name of Person Mailing Correspondence

\*This certificate may only be used if paying by deposit account.




Signature

Dated: May 16, 2001

Paula A. Borden  
Reg. No. 42,344  
Bozicevic, Field & Francis, LLP  
200 Middlefield Road, Suite 200  
Menlo Park, CA 94025  
(650) 327-3400

Return Receipt Postcard

CC:

|  |  |  |
|--|--|--|
| <b>INFORMATION DISCLOSURE CITATION</b><br>Form PTO-1449 (Modified)<br>Use several sheets if necessary<br> | <b>ATTY. DOCKET NO.</b><br>CONN001     | <b>RECEIVED</b><br>SERIAL NO. 09/780,752<br>MAY 24 2001<br>TECH CENTER 1600/2900 |
|  | <b>APPLICANT</b><br>Contact at         |  |
|  | <b>FILING DATE</b><br>February 9, 2001 | <b>GROUP</b><br>Unassigned   |

### U.S. PATENT DOCUMENTS

| Examiner Initial |    | Document Number | Date       | Name           | Class | Subclass | Filing Date<br>If Appropriate |
|------------------|----|-----------------|------------|----------------|-------|----------|-------------------------------|
| swl              | AA | 4,624,804       | 11/25/1986 | Voelter et al. | _____ | _____    |                               |
| swl              | AB | 5,166,191       | 11/24/1992 | Cronin et al.  | _____ | _____    |                               |
| swl              | AC | 5,952,296       | 09/14/1999 | Bigazzi        | _____ | _____    |                               |


### FOREIGN PATENT DOCUMENTS

|     |    | Document Number | Date       | Country | Class | Subclass | Translation |
|-----|----|-----------------|------------|---------|-------|----------|-------------|
| swl | AD | WO 95/07711     | 03/23/1995 | PCT     | _____ | _____    |             |
|     |    |                 |            |         |       |          |             |

### OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

|     |    |   |  |  |  |  |  |
|-----|----|---|--|--|--|--|--|
| swl | AE | Charney et al. (1993) "The role of the coronary collateral circulation in limiting myocardial ischemia and infarct size." <i>Am. Heart J.</i> , Vol. 126:937-945.   |  |  |  |  |  |
| swl | AF | Harada et al. (1994) "Basic Fibroblast Growth Factor Improves Myocardial Function in Chronically Ischemic Porcine Hearts." <i>J. Clin. Invest.</i> , Vol. 94:623-630.   |  |  |  |  |  |
| swl | AG | Henry (1999) "Therapeutic Angiogenesis" <i>BMJ</i> , Vol. 318:1536-9.   |  |  |  |  |  |
| swl | AH | Lopez et al. (1998) "VEGF administration in chronic myocardial ischemia in pigs." <i>Cardiovascular Research</i> , Vol. 40:272-281.   |  |  |  |  |  |
| swl | AI | Losordo et al. (1998) "Gene Therapy for Myocardial Angiogenesis." <i>Circulation</i> , Vol. 98:2800-2804.   |  |  |  |  |  |
| swl | AJ | Patel et al. (1999) "Safety of Direct Myocardial Administration of an Adenovirus Vector Encoding Vascular Endothelial Growth Factor 121." <i>Human Gene Therapy</i> , Vol. 10:1331-1348.  |  |  |  |  |  |
| swl | AK | Unger et al. (1994) "Basic fibroblast growth factor enhances myocardial collateral flow in a canine model." <i>Am. J. Physiol.</i> , Vol. 266:H1588-1595.   |  |  |  |  |  |
| swl | AL | Yang et al. (1998) "Substantially Attenuated Hemodynamic Responses to Escherichia coli-Derived Vascular Endothelial Growth Factor Given by Intravenous Infusion Compared with Bolus Injection." <i>The Journal of Pharmacology and Experimental Therapeutics</i> , Vol. 284(1):103-110. |  |  |  |  |  |
|     |    |   |  |  |  |  |  |
|     |    |   |  |  |  |  |  |
|     |    |   |  |  |  |  |  |

F:\forms\word 2k forms\form PTO-1449.doc

|   |                                      |
|---|--------------------------------------|
| <b>EXAMINER</b><br>  | <b>DATE CONSIDERED</b><br>11-18-2002 |
| <b>EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. |                                      |